The U.S. Food and Drug Administration (FDA) approves the first messenger RNA (mRNA) vaccine for seasonal flu. According to multiple reports, the decision follows the agency’s earlier refusal to move forward with the company’s approval request. Both outlets describe that the FDA initially rejected the application earlier in the year, and later reversed course, ultimately approving an mRNA-based shot intended for seasonal influenza. Live Science and the Washington Times both focus on the regulatory sequence, highlighting that the approval represents a milestone for mRNA vaccine technology in flu prevention in the United States. The reports do not dispute the basic timeline: an initial FDA decision against reviewing the request or rejecting it, followed by a subsequent approval. The information presented is centered on the FDA’s actions and the novelty of the vaccine platform for seasonal flu, rather than on clinical results or broader implications beyond the approval itself.
FDA approves first mRNA vaccine for seasonal flu after earlier rejection
The U.S. Food and Drug Administration (FDA) approves the first messenger RNA (mRNA) vaccine for seasonal flu. According to multiple reports, the decision follows the agency’s earlier refusal to move f...
- The FDA approves the first mRNA-based vaccine for seasonal influenza in the U.S.
- The approval follows an earlier FDA decision that rejected or declined to review the original request.
- Both reports describe the FDA reversing its earlier position before granting approval.
- The vaccine is designed for seasonal flu prevention.
- The coverage focuses on the FDA’s regulatory timeline and the vaccine’s mRNA technology.
The Food and Drug Administration's approval of an mRNA vaccine for flu comes after the agency initially refused to review the approval request for the shot.
2 hours agoThe Food and Drug Administration has approved the first messenger RNA-based vaccine for seasonal flu, after rejecting it earlier this year.
3 hours ago
Normal blood pressure, no diabetes and no smoking linked to 13 more dementia-free years
A study reports that avoiding three common health risk factors in midlife is associated with substantially longer dement...
Bills safety C.J. Gardner-Johnson suffers lower-body injury, later returns to practice
Buffalo Bills safety C.J. Gardner-Johnson exits practice after an apparent lower-right-leg or foot injury during an 11-o...
VA launches major study on psilocybin for depression and PTSD
The U.S. Department of Veterans Affairs (VA) is launching a major research study to examine whether psilocybin—commonly...